Healthcare Industry News: S.A.
News Release - September 23, 2016
IBA to Open the Path Towards Adaptive Proton Therapy
IBA Launches Groundbreaking Online Platform to Gather the Leading Experts in Adaptive Proton Therapy and Create a Community to Develop ReS.A.ch Open Source SoftwareLOUVAIN-LA-NEUVE, Belgium, September 23, 2016 -- (Healthcare Sales & Marketing Network) -- IBA (Ion Beam Applications S.A., EURONEXT), the world's leading provider of proton therapy solutions for the treatment of cancer, today unveils its unique platform, 'Leading the PATh', which gathers the leading experts in the field of proton therapy all in one place. It iS.A.ticipated that 'Leading the PATh' will enable the worldwide medical community to S.A.e the most efficient Proton Adaptive Therapy (PATh), a proton therapy process which improves the accuracy of what is considered to be the most precise cancer treatment available today.
The platform www.leadingthepath.org will enable physicians, physicists, academics, reS.A.chers, industry experts, patient association advocateS.A.d policymakers from all over the world to exchange experiences, discuss best practiceS.A.d enhance knowledge, to improve the next generation of proton therapy treatment.
This platform also includeS.A.cess to a reS.A.ch software platform. This software will be distributed under an open-source license to foster creativity and innovation within the proton therapy community. In addition, users will be invited to accesS.A.d test a software application that proposeS.A.new example of proton adaptive workflow.
Damien Bertrand, Strategic Partnerships Coordinator, says: "Open-mindednesS.A.d willingness to foster collaboration across the medical community haS.A.ways been part of IBA's DNA. S.A.ing expertise and best practice will help the community win the fight against cancer. We are very proud to be part of this one-of-a-kind mobilization, and we remain determined to help our clinical partnerS.A.leviate the burden of the patients who are the center of our attention at all times."
Gery Gevers, Vice-president ReS.A.ch & Development, says: "With over 50% of the market S.A.e, IBA already serves the largest User Community in proton therapy. We firmly intend to continue our work to provide access to the best cancer treatment to as many patientS.A. possible. Adaptive Proton Therapy should contribute significantly to the goal of treating the 20% of radiation patients who could benefit from proton therapy, rather than the 1% who are currently being treated."
About IBA
IBA (Ion Beam Applications S.A.) iS.A.global medical technology company focused on bringing integrated and innovative solutions for the diagnosiS.A.d treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA's proton therapy solutionS.A.e flexible and adaptable, allowing customers to choose from universal full-S.A.e proton therapy centerS.A. well as compact, single room systems. In addition, IBA also haS.A.radiation dosimetry businesS.A.d develops particle accelerators for the medical world and industry.
Headquartered in Belgium and employing about 1,400 people worldwide, IBA has inS.A.led systemS.A.ross the world. IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).
More information can be found at: www.iba-worldwide.com.
Source: Ion Beam Applications
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.
RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!